Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etirinotecan pegol - JenKem Technology

Next Previous
Drug Profile

Etirinotecan pegol - JenKem Technology

Alternative Names: JK-1201l; PEG-irinotecan - JenKem; Pegylated irinotecan - 3SBio; Pegylated irinotecan - JenKem; SSS 22

Latest Information Update: 30 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JenKem Technology
  • Developer 3SBio; JenKem Technology
  • Class Alkaloids; Antineoplastics; Camptothecins; Heterocyclic compounds with 4 or more rings; Indolizines; Piperidines; Polyethylene glycols; Quinolines
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 19 Sep 2024 JenKem Technology plans a phase I trial for Triple negative breast cancer (Metastatic disease, Second-line therapy or greater) (Iv, Infusion) (NCT06586866)
  • 03 Sep 2024 JenKem Technology plans a phase III trial for Small cell lung cancer (Second-line therapy or greater) in September 2024 (NCT06581380)
  • 11 Nov 2021 Phase-I/II clinical trials in Small cell lung cancer (Second-line therapy or greater) in China (IV) (NCT05158491)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top